Study of the Safety and Efficacy of Roxadustat in the Treatment of Heart Failure With Chronic Kidney Disease and Anemia
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 300 participants.
Also called NCT05691257
- Study
- In this atlas
Overview
- Design
- Interventional study; non-randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 300 participants
- Registry
-
NCT05691257
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Unknown status
Technical summary
Registry record NCT05691257. Non-randomized; no masking; primary purpose treatment. Start 2023-02-01 (anticipated); primary completion 2023-08-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study of the Safety and Efficacy of Roxadustat in the Treatment of Heart Failure With Chronic Kidney Disease and Anemia
- Condition
- Heart Failure
- Condition
- Chronic Kidney Diseases
- Condition
- Anemia
- Intervention (Drug)
- Roxadustat
- Intervention (Drug)
- Recombinant human eythropoietin and/or Iron agents
- Lead sponsor
- China-Japan Friendship Hospital
Record details
- Record id
cardio:ct-nct05691257- Content hash
ee1923b3d341824af7b101f9e4e6c4f3d955f83526877258328e2e4d1cd0f4ab